ProQR Therapeutics (PRQR) Expected to Announce Earnings on Thursday

Key Points

• ProQR Therapeutics is set to announce its Q2 2025 earnings on Thursday, August 14th, with analysts predicting a loss of ($0.08) per share.
• Shares of ProQR Therapeutics are currently trading at $2.06, down 2.8%, with a fifty-two week high of $4.62 and a low of $1.07.
• Several analysts have issued ratings for ProQR, with a consensus rating of "Moderate Buy" and an average target price of $8.00.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect ProQR Therapeutics to post earnings of ($0.08) per share and revenue of $5.01 million for the quarter.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). The firm had revenue of $4.89 million during the quarter, compared to analysts' expectations of $4.90 million. ProQR Therapeutics had a negative net margin of 157.04% and a negative return on equity of 53.49%. On average, analysts expect ProQR Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ProQR Therapeutics Trading Up 5.9%

PRQR traded up $0.12 during trading on Friday, reaching $2.17. The stock had a trading volume of 312,555 shares, compared to its average volume of 424,833. The company has a market capitalization of $228.31 million, a price-to-earnings ratio of -6.20 and a beta of 0.43. The stock's 50 day moving average is $2.08 and its two-hundred day moving average is $1.88. ProQR Therapeutics has a one year low of $1.07 and a one year high of $4.62.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PRQR. Evercore ISI reiterated an "outperform" rating on shares of ProQR Therapeutics in a report on Friday, July 11th. Oppenheimer dropped their target price on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. JMP Securities restated a "market outperform" rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a research report on Friday, June 27th. Chardan Capital reaffirmed a "buy" rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research note on Friday. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a report on Friday, June 27th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, ProQR Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $8.00.

Institutional Trading of ProQR Therapeutics

A hedge fund recently raised its position in ProQR Therapeutics stock. Jane Street Group LLC increased its holdings in ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) by 699.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 91,120 shares of the biopharmaceutical company's stock after purchasing an additional 79,720 shares during the period. Jane Street Group LLC owned 0.09% of ProQR Therapeutics worth $121,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).